Clinical utility of monitoring free drug levels

Dasgupta, Amitava; Krasowski, Matthew D.

doi:10.1016/b978-0-12-815849-4.00003-7

Cited by 1 publication

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2) indicated that the electrochemical approach possibly detects the protein-unbound fraction of pazopanib and that the method with acetonitrile can analyse the 'total' fraction underlying clinically relevant pharmacokinetic principles and parameters. 13 Osteryoung square wave stripping (OSWS) voltammetry offers higher sensitivity and a broader dynamic range for measurement of analytes than cyclic voltammetry does. 22 Indeed, this notion was confirmed in PBS containing pazopanib by means of a BDD chip (Supplementary Figure 4).…”

Section: Optimisation Of the Potential Protocol For The Measurement O...mentioning

confidence: 99%

“…5 Another key issue of TDM is that in plasma, 'total drug concentration', which is the sum of a protein-bound fraction and a protein-unbound (free) fraction, is currently measured and interpreted in terms of pharmacokinetic principles and relevant clinical parameters. 13 Accordingly, less expensive systems for rapid and easy determination of a total concentration are in demand. To address this issue and the problems mentioned above, in this study, we propose a simple electrochemical approach involving a boron-doped diamond (BDD) electrode without any engineering modifications.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A simple strategy for low-cost portable monitoring of plasma drug concentrations using a sustainable boron-doped-diamond chip

Saiki¹,

Ogata

Sawamura

et al. 2022

Preprint

View full text Add to dashboard Cite

Monitoring of plasma drug concentrations is required for effective and safe pharmacotherapies. Recent technical advances gave rise to various portable or wearable biosensors for rapid on-site monitoring. These devices are not yet popular owing to not only insufficient evaluation of accuracy on clinical samples and sensor-to-sensor variability but also the need for complicated costly fabrication processes. To address these bottlenecks, here, we describe a simple strategy based on boron-doped diamond (BDD) without any engineering modifications. As a test compound, we selected pazopanib, a molecular-targeting anticancer drug whose monitoring is recommended. When assaying rat plasma spiked with pazopanib, a sensing system constructed from a ~1 cm2 BDD plate chip detected concentrations in the clinically relevant range. The response was stable in a series of 60 measurements on the same chip, indicating excellent repeatability of the assay and high sustainability of the material. When plasma samples collected from orally treated healthy rats or patients with cancers were analysed with the system, the results overall matched the concentrations determined by liquid chromatography with mass spectrometry. Additionally, the reproducibility of BDD chip–based assays was tested. Finally, we constructed a portable system with a palm-sized sensor containing a BDD chip and demonstrated that the setup successfully quantifies the drug in plasma from ~40 µL of whole blood of a dosed rat within a short turnaround time: ~10 min. This approach with the ‘reusable’ sensor, which can also possibly detect other drug types, may accelerate point-of-testing assays and advance personalised medicine while reducing medical costs.

show abstract

Section: Optimisation Of the Potential Protocol For The Measurement O...mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%